Dyax Corp. Recognized as a “Top Place to Work” by The Boston Globe for Second Year in a Row
November 17 2015 - 8:00AM
Business Wire
Dyax Corp. (NASDAQ: DYAX), a biopharmaceutical company
focused on the development and commercialization of novel
biotherapeutics for unmet medical needs, today announced that it
has been named one of the Top Places to Work in Massachusetts by
The Boston Globe for the second year in a row.
“We are honored to be recognized again by The Boston Globe as
one of the top places to work,” said Gustav Christensen, President
and Chief Executive Officer of Dyax. “At Dyax, we understand the
importance of cultivating a positive atmosphere and hope to
continue to inspire our team members in all of their professional
endeavors. I extend my sincere thanks to all the employees of Dyax
for their hard work and dedication.”
The Boston Globe Top Places to Work 2015 magazine was published
in The Boston Sunday Globe on November 15 and will also be featured
on BostonGlobe.com/topplaces. Dyax ranked 2nd out of all
Medium-sized Massachusetts employers, defined as companies with
100-249 employees.
The rankings in the Top Places to Work are based on confidential
survey information collected by Workplace Dynamics, an independent
company specializing in employee engagement and retention, from
nearly 77,000 individuals at 357 Massachusetts organizations.
About DyaxDyax is a biopharmaceutical company focused on
the development and commercialization of novel biotherapeutics for
unmet medical needs. The Company is developing DX-2930, a fully
human monoclonal antibody, for the prevention of HAE attacks.
Additionally, Dyax markets KALBITOR® (ecallantide) for the
treatment of acute attacks of HAE in patients 12 years of age and
older.
Both DX-2930 and KALBITOR were identified using Dyax's
proprietary phage display technology. Dyax has broadly licensed
this technology under its Licensing and Funded Research Portfolio
(LFRP). The current portfolio includes one FDA approved product,
Eli Lilly and Company's CYRAMZA (ramucirumab), for which Dyax
receives royalties, and multiple product candidates in various
stages of clinical development for which the Company is eligible to
receive future milestones and royalties.
For additional information about Dyax, please visit www.dyax.com.
For additional information about KALBITOR, including full
prescribing information, please visit www.KALBITOR.com.
DisclaimerThis press release contains forward-looking
statements. Statements that are not historical facts are based on
Dyax’s current expectations, beliefs, assumptions, estimates,
forecasts and projections about the industry and markets in which
Dyax operates. The statements contained in this release are not
guarantees of future performance and involve certain risks,
uncertainties and assumptions, which are difficult to predict.
Therefore, actual outcomes and results may differ materially from
what is expressed in such forward-looking statements because of
risks, uncertainties and assumptions involved in any future
projections. There are many factors that could cause actual results
to differ from these forward-looking statements, including: risks
and uncertainties relating to the clinical development of DX-2930;
Dyax’s dependence on the expertise, effort, priorities and
contractual obligations of third parties in the development of
DX-2930 and in the marketing, sales and distribution of KALBITOR;
competition from new and existing treatments for HAE; the
uncertainty of patent and intellectual property protection relating
to DX-2930, KALBITOR and the LFRP; Dyax's dependence on licensees
and collaborators for development, clinical trials, manufacturing,
sales and distribution of product candidates in the LFRP;
uncertainties as to whether one or more product candidates in the
LFRP will achieve development and regulatory milestones and be
commercialized and generate royalties; uncertainties regarding
Lilly's ability to successfully market CYRAMZA for the treatment of
advanced gastric cancer; and other risk factors described or
referred to in Item 1A, “Risk Factors” in Dyax’s most recent Annual
Report on Form 10-K and other periodic reports filed with the
Securities and Exchange Commission. Dyax cautions investors not to
place undue reliance on the forward-looking statements contained in
this release. These statements speak only as of the date of this
release, and Dyax undertakes no obligations to update or revise
these statements, except as may be required by law.
Dyax, the Dyax logo and KALBITOR are registered trademarks of
Dyax Corp.
CYRAMZA is a trademark owned by or licensed to Eli Lilly and
Company, its subsidiaries, or affiliates.
View source
version on businesswire.com: http://www.businesswire.com/news/home/20151117005270/en/
Dyax Corp.Jennifer Robinson, 617-250-5741Director, Investor
Relations and Corporate Communicationsjrobinson@dyax.com
Dyax (NASDAQ:DYAX)
Historical Stock Chart
From Mar 2024 to Apr 2024
Dyax (NASDAQ:DYAX)
Historical Stock Chart
From Apr 2023 to Apr 2024